Indole Alkaloids from Plants as Potential Leads for Antidepressant Drugs: A Mini Review

Depression is a highly prevalent global disorder characterised by low mood, anhedonia, cognitive symptoms and disturbances of sleep and appetite. Neurotransmitter imbalances—most notably of serotonin, but also norepinephrine and dopamine—are described as major contributors to depressive states, and current pharmacotherapy typically targets these systems. Synthetic antidepressants such as tricyclic antidepressants and selective serotonin reuptake inhibitors are widely used, but adverse effects and variable efficacy have encouraged interest in plant-derived therapies. Ghosh and colleagues set out to review plant-derived indole alkaloids and related indole-containing phytochemicals as potential leads for antidepressant drug development. The paper aims to collate evidence on specific plants and isolated compounds that exhibit central nervous system activity, to discuss structure–activity relationships that link indole chemistry to serotonergic and other neuroreceptor actions, and to identify gaps where further phytochemical and pharmacological characterisation is needed.

This work is presented as a mini review compiled through bibliographic searches of scientific journals and literature identified via the Web of Science electronic database. The extracted text indicates a narrative synthesis of chemical structures and reported pharmacological activities rather than a formal systematic review. The paper does not provide explicit details about search dates, inclusion and exclusion criteria, study selection procedures, or formal quality/risk-of-bias assessment. Consequently, the review appears to be a selective, literature-based overview that integrates phytochemical descriptions, reported in vitro and in vivo pharmacology, and examples of clinical data where available. Where experimental models are discussed, the authors draw on reported in vitro receptor and enzyme studies, in vivo animal behavioural models (for example mouse models of behavioural despair), and the limited human clinical trial data available for some botanicals (notably kava). Structure–activity and molecular docking observations are summarised from prior pharmacological and medicinal chemistry studies cited in the literature.

The review highlights four plants of particular relevance: Passiflora incarnata (passion flower), Mitragyna speciosa (kratom), Piper methysticum (kava) and Valeriana officinalis (valerian). Two of these—P. incarnata and M. speciosa—contain characterised indole alkaloids, while kava and valerian contain compounds with indole-like features or other indole-containing substructures that may be pharmacologically relevant. Passiflora incarnata: The authors report isolation of several indole alkaloids from passion flower, including harman, harmol, harmine, harmalol and harmaline. Pharmacologically, P. incarnata extracts have been reported to exhibit a benzodiazepine-like profile and to act via GABAergic mechanisms, consistent with their traditional use as sedatives and anxiolytics. Mitragyna speciosa: Mitragynine is identified as the major indole alkaloid in kratom, with related alkaloids speciogynine, paynantheine and speciociliatine. The review cites animal studies in which aqueous or alkaloidal extracts produced antidepressant-like effects in behavioural despair paradigms. One study noted mitragynine’s influence on the hypothalamic–pituitary–adrenal (HPA) axis, suggesting a neuroendocrine component to its actions. Piper methysticum (kava): Active constituents are primarily lipophilic kavalactones (at least seven identified), including dihydromethysticin; these compounds interact with multiple neurotransmitter systems (dopaminergic, serotonergic, GABAergic, glutamatergic), inhibit monoamine oxidase B (MAO-B) in some reports, and act on ion channels. The authors report that lipid-soluble extracts retain most pharmacological activity versus aqueous extracts. Importantly, double-blind placebo-controlled human trials have demonstrated anxiolytic effects of kavalactones, improved sleep quality, and no detrimental effects on mental or motor function—supporting kava as a potential benzodiazepine alternative for anxiety and related symptoms. Valeriana officinalis: Valerenic acid and valepotriates are described as principal active constituents used in sedative preparations. Valepotriates are chemically unstable (thermolabile, acid- and base-sensitive). Mechanistically, valerian preparations are reported to interact with the GABAergic system—via inhibition of GABA transaminase, modulation of GABA receptors/benzodiazepine binding sites, and interference with GABA uptake—supporting anxiolytic and hypnotic effects and potential usefulness during benzodiazepine withdrawal. Experimental models and evidence base: The authors note that most studies reviewed were in vivo animal investigations, fewer were in vitro, and only kava had undergone clinical trials among the plants discussed. Reported pharmacological outcomes vary between preparations and geographic sources, reflecting variation in secondary metabolite profiles. Indole scaffold and medicinal chemistry: The paper provides a chemical and pharmacological rationale for interest in indole alkaloids. Indoles are bicyclic systems (a six‑membered benzene fused to a five‑membered nitrogen-containing pyrrole) that share structural similarity with serotonin, enabling interactions with serotonin receptors (5‑HT families) and other G protein–coupled receptors. The authors discuss structure–activity relationship (SAR) observations: the indole NH and π-electron density contribute to receptor interactions (hydrogen bonding, π–π and cation–π interactions), though some studies indicate the NH is not absolutely required for activity at certain receptors (for example some 5‑HT2 responses). Examples from medicinal chemistry include bioisosteric modification (benzofurans, benzothiophenes, azaindoles) used to modulate solubility, receptor affinity and oral bioavailability; molecular docking studies suggest 2‑phenyl‑indole scaffolds can occupy conserved and non‑conserved receptor subpockets, explaining selectivity differences. The review also highlights that many marketed drugs contain indole substructures and that plant-derived indole alkaloids (and derivatives such as reserpine, vinblastine) have long pharmacological histories. Limitations in the evidence: Across the cited studies, the active constituent(s) responsible for antidepressant effects are often unresolved; crude or semi‑purified extracts predominate, and biochemical variability tied to geography, climate and plant nutrition undermines reproducibility. The authors also note that much of the reliable pharmacological evidence comes from synthetic indole analogues rather than from fully characterised natural products.

Ghosh and colleagues interpret the assembled evidence as supportive of plants as a valuable source of indole-containing lead structures for antidepressant drug discovery. They argue the structural similarity between the indole scaffold and endogenous serotonin provides a plausible mechanistic basis for neurological activity, and that indole chemistry has yielded numerous pharmacologically important molecules. The review emphasises several constraints that temper enthusiasm. Many plant studies use crude extracts and do not isolate or identify the single active principle, producing heterogeneous and sometimes non‑reproducible results. Geographic and ecological variation alters secondary metabolite content, complicating generalisation of findings. Chemical instability of certain constituents (for example valepotriates) and the synthetic inaccessibility of some complex natural indole alkaloids are further obstacles. The authors also acknowledge that relatively few clinical trials exist for the botanicals discussed, with most pharmacological data originating from in vivo animal models or in vitro receptor studies. On the basis of these limitations, the authors recommend targeted phytochemical work (isolation and structural characterisation), metabolomics studies to map active metabolite profiles, and rigorous in vitro and in vivo pharmacological testing to define dose–response relationships and mechanisms. They also highlight the value of medicinal chemistry to derive bioisosteres and more drug‑like analogues when natural compounds are unstable or not synthetically tractable. Overall, the investigators present plant indole alkaloids as promising but underexplored leads that require more systematic pharmacological and chemical development before clinical application.

The review concludes that most plant remedies investigated for psychiatric effects remain crude or semi‑purified and that observed in vitro and in vivo results are inconsistent across regions and preparations. Ghosh and colleagues advocate for concerted efforts to isolate active principles, perform phytochemical identification and metabolomics, and carry out thorough in vitro and in vivo evaluations. They note that while synthetic indole alkaloids have already proven useful in medicine, many naturally occurring indole alkaloids remain difficult to synthesise and under‑studied. In sum, the authors regard plant-derived indole alkaloids as a reservoir of valuable starting points for future antidepressant development and encourage further research to realise this potential.